LAS VEGAS, NV, UNITED STATES, January 15, 2025 /EINPresswire / -- The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.

Topical ET-02 demonstrated successful results in its first-in-human clinical trial for the treatment of androgenic alopecia, Eirion Therapeutics announced in a press release. “Right now ...

An increase in healthcare spending is being driven by an increase in the number of initiatives being undertaken by organizations such as the National Alopecia Treatment Areata Foundation and the ...

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to ...

And here is the kicker—stress can actually lead to more hair loss, creating a vicious cycle. While daily shedding is part of the natural hair cycle, noticing patchy hair loss could be a sign of ...

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to ...

Watch video. New data show ritlecitinib plus phototherapy beneficial for nonsegmental vitiligo In patients with active nonsegmental vitiligo, ritlecitinib (Litfulo, Pfizer) monotherapy or paired ...

Ritlecitinib (Litfulo) acts as an anti-inflammatory agent. It is formulated as hard capsules for oral route of administration. Litfulo is indicated for the treatment of Alopecia areata for adults and ...

"Obviously it's my favorite thing, and it's changed my life in so many ways," continues Tisdale, who has partnered with Pfizer and Litfulo, an FDA-approved pill for people 12 and older with severe ...